

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 February 2005 (24.02.2005)

PCT

(10) International Publication Number
WO 2005/016870 A1

(51) International Patent Classification⁷: **C07C 235/38**,
C07D 307/52, 213/65, 231/12, 271/06, 333/24, A61K
31/4412, A61P 9/10

(21) International Application Number:
PCT/GB2004/003528

(22) International Filing Date: 13 August 2004 (13.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0319124.4 14 August 2003 (14.08.2003) GB

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, PO Box 7929, Philadelphia,
Pennsylvania 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CAMPBELL, Mathew** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **HATLEY, Richard, Jonathan** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **HEER, Jag, Paul** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). **MASON, Andrew, McMurtre** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **NICHOLSON, Neville, Hubert** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). **PINTO, Ivan, Leo** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **RAHMAN, Shahzad, Sharooq**

[GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). **SMITH, Ian, Edward, David** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB).

(74) Agent: **THORNLEY, Rachel, Mary**; GlaxoSmithKline, Corporate Intellectual Property (CN925.1) 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 2-SUBSTITUTED BENZOIC ACID DERIVATIVES AS HM74A RECEPTOR AGONISTS



(I)

(57) Abstract: Therapeutically active anthranilic acid derivatives of Formula (I) wherein R₁, R₂ and Z are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in therapy, particularly in the treatment of diseases in which under-activation of the HM74A receptor contributes to the disease or in which activation of the receptor will be beneficial, are disclosed.